Illustration: Aïda Amer/Axios
Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.
Why it matters: The raise gives Pathos AI more firepower to advance its cancer drugs, buoyed by investor enthusiasm for AI-driven drug development.
